Semaglutide 1 Month Results: What Actually Happens in the First Four Weeks

You're on your starter dose: here's what that means

Imagine it's a Tuesday morning, three weeks into treatment. The pen is in your fridge, you've had two injections, and the scale has barely moved. That experience is more common than the forums suggest, and it makes complete sense once you understand what the first pen is actually doing.

Wegovy (semaglutide) begins at 0.25 mg weekly for the first four weeks. This dose exists to let your body adjust to the medicine, not to produce significant weight loss. The prescribing schedule, set out in the NHS semaglutide guidance, steps the dose upward roughly every four weeks (through 0.5 mg, 1.0 mg, 1.7 mg) before reaching the 2.4 mg maintenance level. Each step does more than the last. Expecting the starter dose to deliver the same results as 2.4 mg is a bit like expecting a car to reach motorway speed in first gear.

That said, something real is usually happening at week four: many people notice food feels less urgent, portions feel more satisfying, and cravings (particularly for high-calorie foods) are quieter. Those appetite shifts are the biological signal that the medicine is working, even when the number on the scales is only a few pounds different. If you want a quick check on whether early changes are tracking, weigh yourself on the same morning, at the same time, before eating. One consistent data point beats three inconsistent ones every time.

For a fuller picture of how the treatment trajectory develops, the Wegovy timeline page covers what changes at each dose stage.

Semaglutide results at one month versus what the trial data show

The landmark evidence for semaglutide 2.4 mg comes from the STEP 1 trial, published in the New England Journal of Medicine, which followed adults with obesity over 68 weeks. Average weight loss reached around 15% of starting body weight by the end of the study. That figure is often quoted, but it almost never describes where participants stood at week four.

Weight loss on semaglutide tends to follow a curve: gentle at first, steeper through months two to six as the dose climbs, then tapering as the body approaches its new set point. By the end of month one, participants in STEP 1 were typically still on 0.25 mg or just moving to 0.5 mg. The meaningful reduction (the kind that registers as clothes fitting differently) tends to arrive from month two onward, which is why two-month results look noticeably different from four-week results.

Comparing your own week-four number against a final-trial-average is an unfair test. The better question at the one-month mark is whether appetite has shifted and whether side effects are settling. Those are the signs a clinician looks for when deciding whether the dose should step up.

If you're curious what cost looks like alongside the clinical picture, the Wegovy pricing page explains what a full private treatment programme includes.

Side effects in week one to four, and when to act

The first month is when GI side effects are most likely to appear. Nausea is the most frequently reported; loose stools, indigestion, burping and fatigue also come up. For most people these are mild to moderate and tend to ease within the first one to two weeks of a new dose. Eating smaller meals, staying hydrated and avoiding very fatty or spicy food during the adjustment period can help, though your prescriber and the Patient Information Leaflet are the right sources for personalised advice.

A small number of people experience more persistent or severe symptoms. The thing to take seriously (and act on promptly) is severe, persistent stomach pain that spreads toward the back, which can be a sign of pancreatitis. The MHRA highlighted acute pancreatitis as a known but infrequent risk for GLP-1 medicines in January 2026; if that symptom pattern appears, seek urgent medical attention rather than waiting for your next check-in.

Signs that are worth reporting to your prescriber rather than managing alone: symptoms that do not settle after two weeks, significant vomiting that is affecting hydration, or anything that feels outside the typical adjustment pattern. Your aftercare team is there for exactly this kind of question. Our prescribers and what that support looks like is described on the clinical team page.

The broader Wegovy overview covers side effects and licensing in more detail for anyone at the research stage.

What month one really tells you about the months ahead

The one-month point is more useful as a signal than a result. Appetite quieter? GI symptoms manageable and beginning to ease? Those are encouraging signs. No meaningful scale change but appetite unchanged and symptoms rough? That picture is worth discussing with your prescriber before the next dose step.

Semaglutide results at three months look substantially different from week four, the three-month results page goes into what typically shifts as the dose reaches the upper ranges. For people who want to see how the trajectory plays out further, the full semaglutide results overview draws on the complete trial data.

These are prescription medicines, and a prescriber decides both whether to start treatment and how to manage the dose progression. If you're at the stage of deciding whether to begin, check your eligibility with our clinical team, consultations are free, and a GPhC-registered prescriber reviews every application the same day it arrives.